A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Inclusion Criteria:

* Signed informed consent
* Willingness to undergo tumor biopsy and disease that is amenable to biopsy (Cohort 1 only)
* Age \>=18 years old
* Advanced, histologically documented carcinoma of the ovary
* Measurable disease with at least one lesion that can be accurately measured per RECIST in at least one dimension (longest dimension recorded). Each lesion must be \>=20 mm when measured by conventional techniques, including palpation, plain X-ray, CT, and MRI, or \>=10 mm when measured by spiral CT.
* Or, clinically or radiologically detectable disease (e.g., ascites, peritoneal deposits, mesenteric thickening or lesions that do not fulfill RECIST for measurable disease). In addition, the subject must have two consecutive pre-treatment CA 125 levels that are both greater than 2× the institutional upper limit of normal (ULN) and \>=40 IU/mL, taken at least 1 week and not more than 3 months apart. The second of the two measurements of CA 125 level should not be drawn within 28 days following the screening biopsy. The later value must be within 2 weeks of starting rhuMAb 2C4 treatment.
* One or more prior platinum-based chemotherapeutic regimens for the management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound
* Life expectancy \>=12 weeks
* ECOG performance status 0 or 1
* Use of an effective means of contraception (for women of childbearing potential)
* Granulocyte count \>=1500/uL, platelet count of \>=75,000/uL, and hemoglobin \>=9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbopoeitin \[Aranesp\] is permitted)
* Serum bilirubin \<=1.5× the ULN and alkaline phosphatase, AST, and ALT \<=2.5× ULN (ALT, AST, and alkaline phosphatase \<=5× ULN for subjects with liver metastases)
* Serum creatinine \<=1.5× ULN
* International normalized ratio (INR) \<1.5 and activated partial thromboplastin time (aPTT) \<1.5 ULN (except for subjects receiving warfarin)

Exclusion Criteria:

* Prior treatment with experimental anti-cancer agents within 4 weeks prior to Day 1 (the day on which the first rhuMAb 2C4 infusion is administered)
* Prior treatment with HER pathway inhibitors (e.g., Herceptin \[Trastuzumab\], Iressa \[gefitinib\], Tarceva \[erlotinib hydrochloride\], C225, CI1033, and TAK165)
* History or clinical evidence of central nervous system or brain metastases
* Ejection fraction, determined by ECHO, \<50%
* Uncontrolled hypercalcemia (\>11.5 mg/dL)
* Prior exposure to doxorubicin or liposomal doxorubicin \>360 mg/m2 , mitoxantrone \>120 mg/m2 , or idarubicin \>90 mg/m2
* History of other malignancies within 5 years of Day 1 except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer
* History of serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure \>100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)
* Ongoing liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
* Known human immunodeficiency virus infection
* Pregnancy or lactation
* Major surgery or significant traumatic injury within 3 weeks prior to Day 1 with the exception of tumor biopsy for the purposes of the study
* Inability to comply with study and follow-up procedures
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications